Video Insights
Advertisement
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
New therapies, such as TP-3654, are currently being explored in combination studies.
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
Drs. Winer, Daver, and Abaza discuss the optimal treatment for older patients with AML.
Advertisement
Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.
Venetoclax plus obinutuzumab was associated with longer PFS compared with chemoimmunotherapy.
There were no significant differences in OS or PFS between allogeneic HSCT and autologous HSCT.
James Berenson, MD, of the Berenson Cancer Center, discusses the launch of the Myeloma BioBank.
The 2024 Society of Hematologic Oncology (SOHO) Annual Meeting will take place September 4-7 in Houston, Texas.
Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL.
Dr. Rodríguez-Otero shares the MRD analysis from the phase III PERSEUS trial at the 2024 ASCO Annual Meeting.
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
Drs. Winer, Daver, and Abaza share their thoughts on the next major breakthroughs in the treatment of AML.
Drs. Winer, Daver, and Abaza share their thoughts and experiences with emavusertib in patients with AML.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
Drs. Winer, Daver, and Abaza discuss the major breakthroughs in the treatment of acute myeloid leukemia.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.